From Fred Alger Management: Cabaletta是一家临床阶段的生物技术公司,专注于发现和开发自身免疫性疾病的靶向细胞疗法。
该公司的主要候选药物 CABA-201 是一种治疗狼疮和肌炎的细胞疗法,美国食品和药物管理局已接受 CABA-201 的新药申请,为 1/2 期的初步读数...查看全文
产业链观察2022-10-11 19:19
药闻▶2022年10月11日,中国南京和上海,美国宾夕法尼亚州费城和加利福尼亚州圣何塞,——驯鹿生物(“IASO Bio”),一家处于临床阶段、致力于细胞创新药物开发的生物制药公司与$Cabaletta Bio(CABA)$ ,一家致力于针对自身免疫性疾病患者开发和商业化的首个靶向细胞疗法的临床阶段...查看全文
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02, 7.01, 8.01, and 9.01 Accession Number: 0001193125-24-003872 Act: 34 Size: 9 MB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-071689 Size: 10 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-065521 Size: 10 KB 网页链接
$Cabaletta Bio(CABA)$ 144 Report of proposed sale of securities Accession Number: 0001950047-23-005215 Act: 33 Size: 6 KB 网页链接
$Cabaletta Bio(CABA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-23-061528 Act: 34 Size: 8 MB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001193125-23-274053 Act: 34 Size: 4 MB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-23-270840 Act: 34 Size: 190 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-054234 Size: 10 KB 网页链接
$Cabaletta Bio(CABA)$ 144 Report of proposed sale of securities Accession Number: 0001950047-23-004577 Act: 33 Size: 6 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-23-248186 Act: 34 Size: 14 MB 网页链接